Evidence map›Paper›PMID 40806424›Full record

ArticleInternational journal of molecular sciences2025

Clinical, Immunological, Radiographic, and Pathologic Improvements in a Patient with Long-Standing Crohn's Disease After Receiving Stem Cell Educator Therapy.

Richard Fox, Boris Veysman, Kristine Antolijao, Noelle Mendoza, Ruby Anne Lorenzo, Honglan Wang, Zhi Hua Huang, Yelu Zhao, Yewen Zhao, Terri Tibbot and 5 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Richard FoxThrone Biotechnologies, Paramus, NJ 07652, USA.
Boris VeysmanThrone Biotechnologies, Paramus, NJ 07652, USA.
Kristine AntolijaoFresenius Medical Care North America, Waltham, MA 02451, USA.
Noelle MendozaFresenius Medical Care North America, Waltham, MA 02451, USA.
Ruby Anne LorenzoFresenius Medical Care North America, Waltham, MA 02451, USA.
Honglan WangThrone Biotechnologies, Paramus, NJ 07652, USA.
Zhi Hua HuangThrone Biotechnologies, Paramus, NJ 07652, USA.
Yelu ZhaoThrone Biotechnologies, Paramus, NJ 07652, USA.
Yewen ZhaoThrone Biotechnologies, Paramus, NJ 07652, USA.
Terri TibbotLife Line Stem Cell Tissue, Cord Blood Bank, New Haven, IN 46774, USA.
Darinka PovrzenicFresenius Medical Care North America, Waltham, MA 02451, USA.
Mary Lauren BayawaFresenius Medical Care North America, Waltham, MA 02451, USA.
Sophia KungValley Radiology Imaging, Los Gatos, CA 95032, USA.
Bassam SaffouriEndoscopy Center of Silicon Valley, Los Gatos, CA 95124, USA.
Yong ZhaoThrone Biotechnologies, Paramus, NJ 07652, USA.ORCID 0000-0002-1571-954X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Crohn's disease is a chronic inflammation affecting the gastrointestinal tract. To date, patients are commonly treated with corticosteroids or more aggressive biologics for high-risk subjects. Stem Cell Educator therapy has been successfully utilized to treat patients with type 1 diabetes and other autoimmune conditions. A 78-year-old patient with long-standing Crohn's disease received one treatment with the Stem Cell Educator therapy, followed by clinical, radiographic, pathological examinations and immune marker testing by flow cytometry. After the treatment with Stem Cell Educator therapy, the patient's clinical symptoms were quickly improved with normal bowel movements, without abdominal pain or rectal bleeding. Flow cytometry analysis revealed a marked decline in inflammatory markers, such as the percentage of monocyte/macrophage-associated cytokine interleukin-1 beta (IL-1β)

Indexed as

Crohn DiseaseAgedHumansMaleTreatment Outcomeautoimmune diseasesCrohn’s diseaseCXCL16IL-1βStem Cell Educator therapy

Identifiers

PMID40806424
PMCPMC12346882

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.